The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and ...

The analysis notes two major market opportunities for NXP900: Single-agent therapy for SRC/YES1-driven tumors, potentially addressing approximately 20,000 lung cancer patients annually Combination ...

a first-in-class SRC/YES1 kinase inhibitor for solid tumors. The main catalyst behind the stock’s sharp rise in 2025 has been investor enthusiasm around upcoming and ongoing presentations of ...

Numerous investigational new drug (IND) applications were also cleared by the FDA, including for the chimeric antigen receptor (CAR) T-cell therapy CTD402 for T-cell acute lymphoblastic ...

NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding ...

The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The ...

Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...

“By simultaneously targeting WEE1 and YES1 kinases, MRANK-106 has demonstrated remarkable preclinical efficacy in multiple hard-to-treat cancers with limited treatment options. We look forward to ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor ...

"By simultaneously targeting WEE1 and YES1 kinases, MRANK-106 has demonstrated remarkable preclinical efficacy in multiple hard-to-treat cancers with limited treatment options. We look forward to ...